OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study
William K. Kelly, Daniel C. Danila, Chia‐Chi Lin, et al.
Cancer Discovery (2023) Vol. 14, Iss. 1, pp. 76-89
Open Access | Times Cited: 29
William K. Kelly, Daniel C. Danila, Chia‐Chi Lin, et al.
Cancer Discovery (2023) Vol. 14, Iss. 1, pp. 76-89
Open Access | Times Cited: 29
Showing 1-25 of 29 citing articles:
The present and future of bispecific antibodies for cancer therapy
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 131
Christian Klein, Ulrich Brinkmann, Janice M. Reichert, et al.
Nature Reviews Drug Discovery (2024) Vol. 23, Iss. 4, pp. 301-319
Closed Access | Times Cited: 131
Cancer therapy with antibodies
Suman Paul, Maximilian F. Konig, Drew M. Pardoll, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 6, pp. 399-426
Closed Access | Times Cited: 55
Suman Paul, Maximilian F. Konig, Drew M. Pardoll, et al.
Nature reviews. Cancer (2024) Vol. 24, Iss. 6, pp. 399-426
Closed Access | Times Cited: 55
A pivotal decade for bispecific antibodies?
Marlena Surowka, Christian Klein
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 20
Marlena Surowka, Christian Klein
mAbs (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 20
Sigma1 inhibitor suppression of adaptive immune resistance mechanisms mediated by cancer cell derived extracellular vesicles
Paola A. Castagnino, Derick A. Haas, Luca Musante, et al.
Cancer Biology & Therapy (2025) Vol. 26, Iss. 1
Open Access | Times Cited: 2
Paola A. Castagnino, Derick A. Haas, Luca Musante, et al.
Cancer Biology & Therapy (2025) Vol. 26, Iss. 1
Open Access | Times Cited: 2
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Tanya B. Dorff, Lisa G. Horvath, Karen A. Autio, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 8, pp. 1488-1500
Closed Access | Times Cited: 13
Tanya B. Dorff, Lisa G. Horvath, Karen A. Autio, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 8, pp. 1488-1500
Closed Access | Times Cited: 13
Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen–targeted therapies
Samir Zaidi, Jooyoung Park, Joseph M. Chan, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 28
Open Access | Times Cited: 10
Samir Zaidi, Jooyoung Park, Joseph M. Chan, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 28
Open Access | Times Cited: 10
T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer
Julia Palecki, Amman Bhasin, Andrew Bernstein, et al.
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 6
Julia Palecki, Amman Bhasin, Andrew Bernstein, et al.
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 6
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Olivier Nolan-Stevaux, Cong Li, Lingming Liang, et al.
Cancer Discovery (2023) Vol. 14, Iss. 1, pp. 90-103
Closed Access | Times Cited: 15
Olivier Nolan-Stevaux, Cong Li, Lingming Liang, et al.
Cancer Discovery (2023) Vol. 14, Iss. 1, pp. 90-103
Closed Access | Times Cited: 15
Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future
Harriet Lampe, Laura Tam, Aaron R. Hansen
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Harriet Lampe, Laura Tam, Aaron R. Hansen
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 4
Antikörper-Wirkstoff-Konjugate in der Uroonkologie
Christopher Darr, Thomas Hilser, Umut-Ulas Yesilyurt, et al.
Im Focus Onkologie (2025) Vol. 28, Iss. 1, pp. 20-25
Closed Access
Christopher Darr, Thomas Hilser, Umut-Ulas Yesilyurt, et al.
Im Focus Onkologie (2025) Vol. 28, Iss. 1, pp. 20-25
Closed Access
T-cell Engagers in Prostate Cancer
Chadi Hage Chehade, Zeynep İrem Özay, Micah Ostrowski, et al.
European Urology (2025)
Closed Access
Chadi Hage Chehade, Zeynep İrem Özay, Micah Ostrowski, et al.
European Urology (2025)
Closed Access
The Role of STEAP1 in Prostate Cancer: Implications for Diagnosis and Therapeutic Strategies
Lingling Zhang, Xinyi Ren, Ran An, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 794-794
Open Access
Lingling Zhang, Xinyi Ren, Ran An, et al.
Biomedicines (2025) Vol. 13, Iss. 4, pp. 794-794
Open Access
Targeting the tumour cell surface in advanced prostate cancer
Cristina Boixareu, Tarek Taha, Varadha Balaji Venkadakrishnan, et al.
Nature Reviews Urology (2025)
Closed Access
Cristina Boixareu, Tarek Taha, Varadha Balaji Venkadakrishnan, et al.
Nature Reviews Urology (2025)
Closed Access
Bispezifische Antikörper in der Therapie des Prostatakarzinoms
Susanne Jung, Jonas S. Heitmann, Martin Pflügler, et al.
Deleted Journal (2025)
Open Access
Susanne Jung, Jonas S. Heitmann, Martin Pflügler, et al.
Deleted Journal (2025)
Open Access
STEAP proteins: Roles in disease biology and potential for therapeutic intervention
Qiaomei Cai, Chao Jing, Xudong Wang, et al.
International Journal of Biological Macromolecules (2025), pp. 142797-142797
Closed Access
Qiaomei Cai, Chao Jing, Xudong Wang, et al.
International Journal of Biological Macromolecules (2025), pp. 142797-142797
Closed Access
PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future
Ann Ayzman, Russell K. Pachynski, Melissa A. Reimers
Current Treatment Options in Oncology (2025)
Open Access
Ann Ayzman, Russell K. Pachynski, Melissa A. Reimers
Current Treatment Options in Oncology (2025)
Open Access
Advances in Targeted Therapy for Metastatic Prostate Cancer
Kabir Grewal, Tanya B. Dorff, Sagar S Mukhida, et al.
Current Treatment Options in Oncology (2025)
Closed Access
Kabir Grewal, Tanya B. Dorff, Sagar S Mukhida, et al.
Current Treatment Options in Oncology (2025)
Closed Access
Precision Targeting in Metastatic Prostate Cancer: Molecular Insights to Therapeutic Frontiers
Whi‐An Kwon, Jae Young Joung
Biomolecules (2025) Vol. 15, Iss. 5, pp. 625-625
Open Access
Whi‐An Kwon, Jae Young Joung
Biomolecules (2025) Vol. 15, Iss. 5, pp. 625-625
Open Access
Immunotherapy toxicities in genito-urinary cancers: insights and challenges for clinicians
Chiara Mercinelli, Chiara Carli, Rosanna Di Vita, et al.
Current Opinion in Urology (2025)
Closed Access
Chiara Mercinelli, Chiara Carli, Rosanna Di Vita, et al.
Current Opinion in Urology (2025)
Closed Access
Left out in the cold: Moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies
Laura H. Porter, Sophie Harrison, Gail P. Risbridger, et al.
The Journal of Steroid Biochemistry and Molecular Biology (2024) Vol. 243, pp. 106571-106571
Open Access | Times Cited: 3
Laura H. Porter, Sophie Harrison, Gail P. Risbridger, et al.
The Journal of Steroid Biochemistry and Molecular Biology (2024) Vol. 243, pp. 106571-106571
Open Access | Times Cited: 3
Bispecific T-cell Engagers in Metastatic Castration-Resistant Prostate Cancer
Chadi Hage Chehade, Georges Gebrael, Neeraj Agarwal
Cancer Discovery (2024) Vol. 14, Iss. 1, pp. 20-22
Closed Access | Times Cited: 2
Chadi Hage Chehade, Georges Gebrael, Neeraj Agarwal
Cancer Discovery (2024) Vol. 14, Iss. 1, pp. 20-22
Closed Access | Times Cited: 2
Developmental Therapeutics in Metastatic Prostate Cancer: New Targets and New Strategies
Jingsong Zhang, Juskaran Chadha
Cancers (2024) Vol. 16, Iss. 17, pp. 3098-3098
Open Access | Times Cited: 2
Jingsong Zhang, Juskaran Chadha
Cancers (2024) Vol. 16, Iss. 17, pp. 3098-3098
Open Access | Times Cited: 2
Tumor-associated antigen targets for novel immune-based strategies in prostate cancer
Amman Bhasin, Patrick Mille, Aditya Eturi, et al.
Journal of Translational Genetics and Genomics (2024) Vol. 8, Iss. 1, pp. 55-76
Open Access | Times Cited: 1
Amman Bhasin, Patrick Mille, Aditya Eturi, et al.
Journal of Translational Genetics and Genomics (2024) Vol. 8, Iss. 1, pp. 55-76
Open Access | Times Cited: 1
Single Cell Analysis of Treatment–Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies
Samir Zaidi, Jooyoung Park, Joseph M. Chan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Samir Zaidi, Jooyoung Park, Joseph M. Chan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Clinical Applications of the Gut Microbiome in Genitourinary Cancers
Charles B. Nguyen, Ulka N. Vaishampayan
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 1
Charles B. Nguyen, Ulka N. Vaishampayan
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 1
